Speaker

Danette L. Daniels, Ph.D. is a Vice President of the Protein Degrader Platform at Foghorn Therapeutics developing therapeutic degraders in the areas of chromatin modulation, epigenetics, and oncology. She was an early leader in the field of targeted protein degradation, pioneering approaches to monitor cellular kinetics of degradation, understand mechanism of action, and co-developed a new PROTAC modality.  She is a member of numerous committees including; AACR Chemistry in Cancer Research Steering Committee, AACR Drug Discovery Section of Experimental Therapeutics, and the HESI TPD Safety Initiative. In 2023 she founded of the Women in TPD and Induced Proximity Initiative which is nearing 700 members. She received her PhD in Biophysics at Yale University and was a postdoctoral fellow at Stanford School of Medicine studying the Wnt signaling pathway.

LinkedIn: Danette Daniels | LinkedIn

Twitter: @danetteldaniels

« Go Back